Business and Economy

Press Statement by Dr. Faisal Shuaib, CEO NPHCDA, on Covid-19 Vaccines

Nigeria is continuing in the process of administering roughly 4 million doses of the Oxford/AstraZeneca vaccine, beginning with our frontline health workers and vulnerable individuals. There has been no change to current plans or supply.

A huge number of countries around the world are administering the Oxford/AstraZeneca vaccine, including much of Europe, and United Kingdom which has administered the most doses of AstraZeneca globally.
The World Health Organization, British and European health regulators all continue to advocate for the use of AstraZeneca.

AstraZeneca’s strong effectiveness against COVID-19 has been demonstrated in clinical and human trials: it has been shown to be 76% effective at preventing COVID-19 and 100% effective at preventing severe disease and hospitalization.
Nigeria’s Health Authorities followed closely recent pronouncements from  Europe’s regulator, the EMA. The Head of the EMA stated that, according to scientific knowledge, there is no evidence to support restricting the use of the vaccine in any population.

The NPHCDA’s priority is the health and safety of the Nigerian people, and our decisions and advice are guided by best practice scientific evidence. We are confident in AstraZeneca’s ability to save lives.

Vaccines save lives!

Signed: Dr. Faisal Shuaib, ED/CEO NPHCDA

Leave a Reply